Damodaran S, O'Sullivan CC, Elkhanany A, Anderson IC, et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol 2023;34:1131-1140.
PMID: 38072513